📰 Sight Biologic News
Sight Biologic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sight Biologic. Real-time updates on events, politics, business and more.
May 7, 2024
GenSight Biologics shares resume trading today Over €9.2 million offering of ABSA composed of a reserved offering aimed at specialized investors and a private placement More than 50% of the...
April 18, 2024
Press Release GenSight Biologics Announces the Filing of its 2023 Universal Registration Document Paris, France, April...
April 4, 2024
Advanced discussions ongoing to secure financing until resumption of early access program expected in Q3 2024 Full alignment sought with regulatory agencies prior to launch of a global Phase III...
January 16, 2024
16.01.2024 - Regulatory News: The Board of Directors of GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the Company), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...
November 15, 2023
15.11.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...
May 31, 2023
Procedures for obtaining preparatory documents for the General Meeting Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on
May 31, 2023
CONVENING OF THE COMBINED GENERAL MEETING ON MAY 25, 2022 GENSIGHT BIOLOGICS A French Société Anonyme ... | May 31, 2023
May 31, 2023
CONVENING OF THE COMBINED GENERAL MEETING ON JUNE 21, 2023 GENSIGHT BIOLOGICS A French Société Anonyme ... | May 31, 2023
May 10, 2023
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for